NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-10-27 16:18இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Bajaj Healthcare Q2 Revenue Up 18.9% to ₹175.9 Cr; Targets ₹900-1,000 Cr Revenue by FY29
Bajaj Healthcare released its Q2 FY27 earnings call transcript, highlighting an 18.9% YoY revenue increase to ₹175.9 crore and a 26.9% YoY rise in PAT to ₹14.1 crore. For H1 FY27, revenue reached ₹341.5 crore (up 15.1% YoY) with PAT at ₹27.8 crore, driven by an 82% YoY rebound in formulation sales and 28.5% growth in API exports. Management guided for ₹900 to ₹1,000 crore in revenue by FY29 with an EBITDA margin of 18% to 21%. Strategic growth drivers include a 250 kg/annum commercial peptide facility commissioning by March 31, 2027, and an oncology API plant slated for Q2 FY28.
உச்சம் நம்பிக்கை
என்ன மாறியதுSubmission of the formal transcript of the Q2 & H1 FY27 earnings conference call detailing growth guidance and project completion roadmaps.
ஏன் இது முக்கியம்Provides strategic clarity on margin trajectory, new peptide and oncology capex timelines, and the growth target of scaling to ₹900-1,000 crore revenue by FY29 from TTM base of ₹420 crore.
Q2 FY27 Revenue: ₹175.9 கோடிQ2 FY27 PAT: ₹14.1 கோடிH1 FY27 Revenue: ₹341.5 கோடிPeptide Capacity: 250 kg per annumFY29 Revenue Target: ₹900 crores to INR1,000 crores
📅 குறுகிய காலம்Earnings transcript provides detailed operational color following results, which may support sentiment given the strong formulation rebound and export growth.
📈 நீண்ட காலம்Achieving the FY29 revenue target implies more than doubling historical annual revenue, contingent on successful commissioning and commercialization of peptide and oncology capacities.
⚠ அபாய எச்சரிக்கைகள்
Execution risks on upcoming peptide (March 2027) and oncology (Q2 FY28) plants
Regulatory approval timing across Brazil (ANVISA) and European filings
Existing debt load of ₹282 Cr relative to cash generation
👀 கவனிக்க வேண்டியவை
Track the execution timelines of the peptide facility (targeted March 2027) and regulatory approvals (ANVISA Brazil and European CEP submissions) in subsequent quarterly updates.
Q2 FY27 PAT Rises 26.9% YoY to ₹14.1 Cr; Revenue Up 18.9% to ₹175.9 Cr
Bajaj Healthcare reported an 18.9% YoY increase in Q2 FY27 revenue from operations to ₹175.9 crore, driven by an 82% surge in formulations revenue (₹41.7 crore) and 28.5% growth in API exports (₹62.6 crore). EBITDA grew 12.2% YoY to ₹32.1 crore with an EBITDA margin of 18.2%, while PAT rose 26.9% YoY to ₹14.1 crore. For H1 FY27, revenue reached ₹341.5 crore (up 15.1% YoY) and PAT expanded to ₹27.8 crore (up 21.1% YoY). Additionally, India Ratings upgraded the company's long-term rating to IND A/Stable from IND A-/Stable.
உச்சம் நம்பிக்கை
என்ன மாறியதுBajaj Healthcare reported strong double-digit growth in Q2 FY27 earnings alongside receiving NCLT approval for the GenRx acquisition and a credit rating upgrade.
ஏன் இது முக்கியம்A sharp rebound in the high-margin formulations business and export APIs is diversifying revenue away from stagnant domestic APIs, while credit rating improvements lower future borrowing costs.
📅 குறுகிய காலம்Earnings commentary from the October 19 call regarding the Cenobamate rollout and the GenRx acquisition integration will be the near-term focus.
📈 நீண்ட காலம்Expansion into high-barrier products like peptides (commissioning in Q4 FY27) and international regulatory approvals (ANVISA, CEPs, KDMF) provide a structural runway for export growth.
⚠ அபாய எச்சரிக்கைகள்
Domestic API sales contracted 6.1% YoY and 22.4% QoQ in Q2 FY27
Execution and integration risks relating to the newly approved GenRx acquisition
👀 கவனிக்க வேண்டியவை
Track the commercial traction of Cenobamate through its 8 marketing partners and progress on the peptide facility commissioning scheduled for Q4 FY27.
NCLT Approves Bajaj Healthcare's Acquisition of Genrx Pharma as Going Concern
Bajaj Healthcare Limited has secured approval from the Hon'ble NCLT, Mumbai Bench, vide an order dated October 13, 2026, to acquire Genrx Pharmaceuticals Private Limited (in Liquidation) on a going concern basis. Following the implementation of terms, Genrx Pharmaceuticals will become a wholly owned subsidiary of the company. The acquisition follows earlier company disclosures from April 2025 regarding the resolution process. Key financial terms, including total acquisition cost and capacity additions, were not disclosed in the filing.
நடுத்தரம் நம்பிக்கை
என்ன மாறியதுThe NCLT Mumbai Bench has formally approved Bajaj Healthcare's acquisition of distressed entity Genrx Pharmaceuticals on a going concern basis.
ஏன் இது முக்கியம்The acquisition expands Bajaj Healthcare's manufacturing footprint and asset base into a wholly owned subsidiary, supporting its long-term formulation and API growth strategy.
NCLT order date: அக்டோபர் 13, 2026Order download date: அக்டோபர் 13, 2026Acquisition cost: வெளியிடப்படவில்லைTTM Revenue context: Rs 420 கோடி
📅 குறுகிய காலம்Positive sentiment from regulatory clearance of a pending distressed asset acquisition; details regarding cash outflow and funding will be key.
📈 நீண்ட காலம்Adds operational capacity to Bajaj Healthcare's existing pharmaceutical portfolio if Genrx assets are revived and integrated cost-effectively.
⚠ அபாய எச்சரிக்கைகள்
Acquisition consideration not disclosed
Turnaround and integration risk of an entity acquired under liquidation
👀 கவனிக்க வேண்டியவை
Monitor upcoming quarterly disclosures for the total acquisition payout, integration timeline, and capacity or revenue contribution from Genrx Pharmaceuticals.
Bajaj Healthcare sets Sep 14, 2026 as record date for ₹1.50/share (30%) final dividend
Bajaj Healthcare Limited has fixed Monday, September 14, 2026, as the record date for determining shareholder entitlement to a final dividend. The proposed dividend is 30%, or ₹1.50 per equity share, for FY 2025-26. Payment remains subject to approval by shareholders at the upcoming Annual General Meeting.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company established the formal record date to determine eligibility for the FY26 final dividend of ₹1.50 per share.
ஏன் இது முக்கியம்Provides dividend clarity for shareholders; representing a modest dividend yield of approximately 0.45% on the current market price of ₹334.
Dividend per share: ₹1.50Dividend percentage: 30%ரெக்கார்ட் தேதி: 14-செப்.-2026Dividend yield at ₹334 price: ~0.45%
📅 குறுகிய காலம்The stock will trade ex-dividend ahead of September 14, 2026, followed by payout post-AGM approval.
📈 நீண்ட காலம்Limited; routine corporate action reflecting ongoing operational cash flows and standard shareholder payouts.
👀 கவனிக்க வேண்டியவை
Investors seeking dividend entitlement must hold shares prior to the ex-dividend date associated with the September 14, 2026 record date.
Bajaj Healthcare receives DCGI approval as first to launch Cenobamate in India
Bajaj Healthcare has received final approval from the Drug Controller General of India (DCGI) to manufacture and market Cenobamate API and Tablets. The company is the first to launch this next-generation antiseizure medication in India, targeting partial-onset seizures in adults. The approval covers six tablet strengths ranging from 12.5 mg to 200 mg. This move strengthens the company's Central Nervous System (CNS) portfolio, which is a key part of its strategy to move into higher-value pharmaceutical products.
உச்சம் நம்பிக்கை
என்ன மாறியதுBajaj Healthcare has moved from a regulatory recommendation to final DCGI approval for manufacturing and marketing Cenobamate API and tablets.
ஏன் இது முக்கியம்Being the first to launch a specific antiseizure medication in India provides a competitive edge in the CNS therapeutic area. This aligns with the company's goal of improving profitability (TTM OPM 17.4%) by focusing on complex and high-value products.
📅 குறுகிய காலம்The stock may see positive sentiment as the first-mover status in a specialized drug category is a notable milestone for a mid-cap pharma player.
📈 நீண்ட காலம்If successfully commercialized, this product could structurally improve the company's product mix and margins within the CNS segment over the next 2-3 years.
⚠ அபாய எச்சரிக்கைகள்
Market adoption rate for a new epilepsy therapy
Potential competition from larger generic manufacturers in the future
Execution risk in scaling the CNS franchise
👀 கவனிக்க வேண்டியவை
Investors should monitor the commercial launch timeline and the subsequent impact on the CNS segment's revenue contribution in the FY27 quarterly results. The first-mover advantage is significant, but the speed of market penetration and potential entry of competitors will determine long-term margin benefits.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
IND A Rating Upgrade: Bajaj Healthcare Debt Facilities Reduced to ₹282 Cr
India Ratings (Ind-Ra) has upgraded Bajaj Healthcare's long-term rating to 'IND A' from 'IND A-' and short-term rating to 'IND A1' from 'IND A2+'. The upgrade is driven by improved credit metrics, with net leverage falling to 2.1x in FY26 from 4.7x in FY24, and interest coverage rising to 4.7x. Revenue grew to ₹611 Cr in FY26 with EBITDA margins expanding to 17.2%. The company is pivoting towards regulated markets and CDMO services, which now account for 10% of total revenue.
உச்சம் நம்பிக்கை
என்ன மாறியதுIndia Ratings upgraded the company's credit profile by one notch and reduced the total quantum of rated debt facilities.
ஏன் இது முக்கியம்A higher credit rating typically leads to lower borrowing costs and reflects the company's successful deleveraging and shift toward higher-margin CDMO and regulated market segments.
Upgraded Long-term Rating: IND ATotal Bank Facilities: ₹282 கோடிFY26 Revenue: ₹611 கோடிNet Leverage (FY26): 2.1xPlanned Capex: ₹50 கோடிCapex vs Net Worth: ~9.4%
📅 குறுகிய காலம்The upgrade provides a positive sentiment boost and confirms the company's improving financial health following a recovery from FY24 losses.
📈 நீண்ட காலம்The strategic shift to CDMO (10% of revenue) and regulated markets, supported by a stronger balance sheet, positions the company for sustainable margin expansion.
⚠ அபாய எச்சரிக்கைகள்
Elongated working capital cycle (200 days)
Regulatory compliance risks at manufacturing plants
Currency volatility (30% revenue in foreign currency)
👀 கவனிக்க வேண்டியவை
Watch for the commissioning of the peptide API facility in Q4FY27 and the company's ability to further reduce its 200-day working capital cycle.
Bajaj Healthcare targets ₹1,000 Cr revenue in 3 years; Q1 FY27 PAT up 14% to ₹13.9 Cr
Bajaj Healthcare reported a steady Q1 FY27 with revenue growing 11.3% YoY to ₹165.6 Cr and PAT rising 14.1% to ₹13.9 Cr. The company is undergoing a structural shift toward high-value segments, including Peptides and Oncology, with a new 250 kg/annum peptide facility slated for Q4 FY27. Management has provided a clear growth guidance of 10-15% for FY27 and a long-term revenue target of ₹900-1,000 Cr within 2-3 years. Notably, the balance sheet has deleveraged significantly, with the Debt-to-Equity ratio falling to 0.45 from 1.19 in FY24.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned from a routine API manufacturer to a high-value specialty player with a focus on Peptides and Oncology, backed by a much stronger balance sheet.
ஏன் இது முக்கியம்The shift toward high-margin science-led APIs and specialized formulations (like Cenobamate) is expected to structurally improve EBITDA margins and drive a significant scale-up in revenue over the next 3 years.
📅 குறுகிய காலம்The stock may react positively to the margin expansion (Gross Margin up 210 bps) and the clear 10-15% growth guidance for the current fiscal year.
📈 நீண்ட காலம்The company's pivot to complex molecules and oncology, combined with a target to double revenue in 3 years, suggests a potential re-rating if execution timelines for new plants are met.
⚠ அபாய எச்சரிக்கைகள்
Execution risk in commissioning high-tech peptide and oncology facilities
Regulatory delays in NCLT approval for the GenRx acquisition
Geopolitical risks impacting export pricing and oil-linked API costs
👀 கவனிக்க வேண்டியவை
Watch for the timely commissioning of the peptide facility in Q4 FY27 and the NCLT approval for the GenRx facility acquisition, as these are critical for the company's ₹1,000 Cr revenue roadmap.
Q1 FY27 Results: PAT up 15.8% to ₹13.7 Cr; Revenue grows 11.3% YoY to ₹165.6 Cr
Bajaj Healthcare reported a strong start to FY27 with revenue rising 11.3% YoY to ₹165.6 Cr, which represents approximately 39.4% of its TTM revenue in a single quarter. Growth was primarily driven by the domestic API segment, which surged 27.1% YoY, offsetting a 4.1% decline in exports caused by geopolitical issues in West Asia. Profitability improved as EBITDA margins expanded to 17.8% from 17.1% YoY, leading to a PAT of ₹13.7 Cr. A key regulatory milestone was achieved as the company became the first in India to receive SEC recommendation for Cenobamate Tablets.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company delivered double-digit growth in revenue and profit while achieving a major regulatory milestone for a next-generation anti-seizure medication.
ஏன் இது முக்கியம்The margin expansion and strong domestic API performance demonstrate operational resilience, while the regulatory progress in regulated markets (EU/UK) and the new R&D center signal a shift toward higher-value products.
Revenue (Q1 FY27): ₹165.6 கோடிPAT (Q1 FY27): ₹13.7 கோடிEBITDA லாப வரம்பு: 17.8%Domestic API Growth: 27.1%Q1 வருவாய் vs TTM வருவாய்: 39.4%
📅 குறுகிய காலம்The stock may see positive sentiment driven by margin expansion and the regulatory breakthrough for Cenobamate.
📈 நீண்ட காலம்Structural growth is supported by the operationalization of the Savli R&D center and increasing approvals in regulated markets, though high debt levels remain a factor to watch.
⚠ அபாய எச்சரிக்கைகள்
Geopolitical disruptions in West Asia impacting exports
High debt levels (₹249 Cr) relative to quarterly earnings
Marginal decline in formulations segment
👀 கவனிக்க வேண்டியவை
Monitor the commercialization timeline for Cenobamate Tablets and the recovery of export revenues as geopolitical tensions stabilize. Watch for the impact of the newly operational Savli R&D center on the company's complex product pipeline.
Bajaj Healthcare First in India to Get SEC Nod for Cenobamate Tablets
Bajaj Healthcare (BHL) has become the first company in India to receive a recommendation from the Subject Expert Committee (SEC) of the CDSCO to manufacture and market Cenobamate Tablets. The recommendation covers six dosage strengths ranging from 12.5mg to 200mg for treating partial-onset seizures in adults. This next-generation antiseizure medication marks a significant entry into the specialty Central Nervous System (CNS) therapy market for the company. The move is expected to enhance BHL's product portfolio and market share in the epilepsy treatment segment.
முக்கிய அம்சங்கள்
First-mover advantage in India for Cenobamate Tablets following SEC recommendation.Recommended for 6 dosage strengths: 12.5mg, 25mg, 50mg, 100mg, 150mg, and 200mg.Targets the high-growth Central Nervous System (CNS) specialty segment for adult epilepsy.Clinical studies indicate significant seizure reduction and high seizure freedom rates for the drug.
👀 கவனிக்க வேண்டியவை
This is a positive regulatory milestone that gives BHL a competitive edge in the CNS segment; investors should monitor the timeline for final marketing approval and commercial launch.
Bajaj Healthcare Closes Trading Window for Business Unit Sale and Q1 FY27 Results
Bajaj Healthcare Limited has announced a trading window closure for designated persons starting June 23, 2026, in relation to the sale of an operational business unit. A second closure will commence on July 1, 2026, for the declaration of un-audited financial results for the quarter ending June 30, 2026. Both windows will remain closed until 48 hours after the respective events (signing of definitive agreements and results declaration). This is a mandatory compliance step under SEBI Insider Trading Regulations.
முக்கிய அம்சங்கள்
Trading window closed from June 23, 2026, due to the sale of an operational business unit.Closure for the business sale remains until 48 hours after the execution of definitive agreements.Quarterly results trading window closure begins July 1, 2026, for the period ending June 30, 2026.Restrictions apply to all Designated Persons and their immediate relatives per SEBI PIT Regulations.The company previously disclosed the business unit sale on June 23, 2026, under Regulation 30.
👀 கவனிக்க வேண்டியவை
Investors should monitor for the formal execution of the business unit sale agreements as this could impact the company's asset base and valuation. No immediate action is required as this is a standard regulatory filing.
Bajaj Healthcare FY26 Revenue Up 12.6% to ₹611 Cr; Net Profit Drops 60% on Exceptional Loss
Bajaj Healthcare reported a 12.6% YoY growth in annual revenue to ₹61,103 Lakhs for FY26. However, the company faced a significant net loss of ₹2,285 Lakhs in Q4 FY26, primarily due to a one-time exceptional item of ₹3,324 Lakhs related to a technical know-how income reversal from a Middle East contract. Annual net profit consequently declined by 60% to ₹1,576 Lakhs. Despite the profit hit, the board recommended a final dividend of ₹1.50 per share and successfully utilized ₹15,000 Lakhs from warrant conversions for debt repayment.
முக்கிய அம்சங்கள்
Annual Revenue from continuing operations grew 12.6% YoY to ₹61,103.14 Lakhs.Q4 FY26 reported a net loss of ₹2,285.06 Lakhs vs a profit of ₹1,117.78 Lakhs in the previous year's quarter.Exceptional loss of ₹3,324.66 Lakhs recognized in Q4 due to reversal of income from a technical know-how arrangement.Board recommended a final dividend of 30% (₹1.50 per equity share) for FY 2025-26.Company utilized ₹15,000 Lakhs from preferential issue proceeds for loan repayment, significantly reducing debt.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's ability to stabilize margins following the one-time income reversal and the progress of the Genrx Pharmaceuticals acquisition. While the debt reduction is a positive structural change, the volatility in contract-based income suggests a need for caution.
Bajaj Healthcare FY26 PAT Rises 27% to ₹545.6 Mn; API Exports Surge 51.6%
Bajaj Healthcare reported a 12.6% YoY revenue growth for FY26, reaching ₹6,110.3 Mn, driven primarily by a robust 51.6% surge in API exports. While Q4 revenue was flat due to domestic API price erosion, PAT from continuing operations grew 19.3% in Q4 and 27.1% for the full year. The company strengthened its balance sheet by raising ₹527 Mn through warrant conversion and expanded its pipeline with 41 new DMF filings in Q4. However, a one-time reversal of income from a Middle East contract due to regional instability impacted the final reported profit.
முக்கிய அம்சங்கள்
FY26 Revenue grew 12.6% to ₹6,110.3 Mn, with API exports jumping 51.6% to ₹1,881.4 Mn.PAT from continuing operations (before exceptional items) increased 27.1% YoY to ₹545.6 Mn in FY26.Company filed 41 DMFs in Q4 FY26, bringing the cumulative total to 110 to target regulated markets.Raised ₹527 Mn through the conversion of 2,079,409 warrants into equity shares to support growth.Cenobamate (anti-epileptic) is on track for a Q2 FY27 launch following Phase III trials.
👀 கவனிக்க வேண்டியவை
Investors should monitor the successful launch of Cenobamate in Q2 FY27 and the scaling of the CDMO segment as key growth drivers. The strong export momentum and regulatory filings suggest a positive shift towards higher-margin regulated markets.
Bajaj Healthcare reported a 12.6% YoY increase in FY26 revenue to Rs. 611.03 crore, though net profit fell significantly to Rs. 15.77 crore from Rs. 39.50 crore in FY25. The Q4 performance was severely impacted by a one-time exceptional loss of Rs. 33.25 crore due to the reversal of technical know-how income linked to Middle East instability. Despite a Q4 net loss of Rs. 22.85 crore, the board recommended a final dividend of Rs. 1.50 per share. The company also strengthened its capital base by raising Rs. 52.71 crore through warrant conversions.
முக்கிய அம்சங்கள்
FY26 Revenue from operations increased to Rs. 61,103.14 lakhs from Rs. 54,260.24 lakhs in FY25.Reported a significant exceptional item of Rs. 3,324.66 lakhs in Q4 FY26 due to income reversal.Total Net Profit for FY26 dropped to Rs. 1,576.61 lakhs compared to Rs. 3,949.55 lakhs in the previous year.Recommended a final dividend of Rs. 1.50 per equity share (30% of face value of Rs. 5).Raised Rs. 5,271.30 lakhs through the conversion of 20,79,409 warrants into equity shares for debt repayment and CAPEX.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution as the sharp decline in profitability and the large income reversal indicate high sensitivity to geopolitical risks. Monitor the successful integration of the Genrx acquisition and the impact of debt repayment on future margins.
Bajaj Healthcare Receives Listing Approval for 20.79 Lakh Equity Shares
Bajaj Healthcare Limited has received in-principle approval from both NSE and BSE for the listing of 20,79,409 equity shares of face value ₹5 each. These shares were allotted following the conversion of warrants previously issued on a preferential basis. The listing will proceed once the company receives confirmation of credit from the depositories (NSDL and CDSL). This move completes a stage of the company's capital raising process, increasing the total outstanding equity shares.
முக்கிய அம்சங்கள்
Listing approval granted for 20,79,409 equity shares of ₹5 face value eachShares issued pursuant to conversion of warrants on a preferential basisIn-principle approval received from both BSE Limited and National Stock Exchange of IndiaNew shares carry distinctive numbers from 31583253 to 33662661Trading to commence post confirmation of credit from NSDL/CDSL
👀 கவனிக்க வேண்டியவை
Investors should account for the slight dilution in Earnings Per Share (EPS) resulting from the increased share capital. No immediate action is required as this is a procedural step following a prior preferential allotment.
Bajaj Healthcare Limited has successfully completed the allotment of 20,79,409 equity shares following the conversion of warrants issued in September 2024. The conversion was executed at a price of ₹338 per share, resulting in a total capital infusion of approximately ₹70.28 crore, with ₹52.71 crore received as the final 75% payment. The allotment includes participation from both promoters and non-promoter public investors, indicating strong confidence in the company's prospects. Consequently, the company's paid-up equity capital has increased to ₹16.83 crore, and no warrants remain outstanding.
முக்கிய அம்சங்கள்
Allotment of 20,79,409 equity shares at an issue price of ₹338 per share (including ₹333 premium).Total funds raised through this warrant exercise aggregate to ₹70.28 crore.Company received ₹52.71 crore as the final 75% balance consideration from 8 allottees.Promoter Sajankumar Rameshwarlal Bajaj's post-issue holding stands at 36.62% (1,23,25,774 shares).Total paid-up share capital increased from 3,15,83,252 to 3,36,62,661 equity shares of ₹5 each.
👀 கவனிக்க வேண்டியவை
The successful conversion of warrants and the resulting capital infusion strengthen the company's balance sheet and reflect promoter commitment. Investors should monitor the company's upcoming quarterly results to see how this additional capital is deployed for growth.
Bajaj Healthcare Shareholders Approve Re-appointment of CMD and 6 Other Directors
Bajaj Healthcare Limited has successfully passed seven special resolutions via postal ballot as of February 19, 2026. Key approvals include the re-appointment of Mr. Sajankumar Rameshwarlal Bajaj as Chairman & Managing Director and Mr. Anil Champalal Jain as Managing Director. The company also appointed three new Non-Executive Independent Directors to its board. While all resolutions passed with the requisite majority, Resolution 7 faced significant dissent from public institutional voters.
முக்கிய அம்சங்கள்
Re-appointment of Sajankumar Rameshwarlal Bajaj as CMD passed with 99.99% of total votes in favor.Three new Independent Directors (Mr. Vaghela, Mrs. Amin, and Mr. Bhavsar) were officially inducted into the board.Total of 19.3 million votes were polled, representing 61.13% of the total outstanding shares.Resolution 7 regarding the re-appointment of Mr. Pakshal Anil Jain saw 99.99% of voting public institutions (599,840 votes) voting against.All 7 resolutions were special resolutions and passed with the required majority as per SEBI regulations.
👀 கவனிக்க வேண்டியவை
The approval ensures management continuity, which is generally stable for the stock. However, investors should monitor the reasons behind the high institutional dissent on Resolution 7 to evaluate any underlying corporate governance concerns.
Bajaj Healthcare Q3 PAT Rises 34% to ₹15.67 Cr; Key Management Re-appointed
Bajaj Healthcare reported a strong 31.3% YoY growth in revenue from operations, reaching ₹161.22 crore for Q3 FY26. Net profit for the quarter surged by 33.7% YoY to ₹15.67 crore, aided by improved performance in continuing operations and significantly reduced losses from discontinued units. The company also announced the re-appointment of its top leadership, including the Chairman and Managing Directors, for another three-year term starting April 2026. Nine-month performance remains robust with total profit increasing to ₹38.62 crore compared to ₹28.32 crore in the previous year.
முக்கிய அம்சங்கள்
Revenue from operations grew 31.3% YoY to ₹16,122.27 lakhs in Q3 FY26.Net profit for the period increased 33.7% YoY to ₹1,567.38 lakhs.9M FY26 total income reached ₹46,215.16 lakhs compared to ₹39,396.27 lakhs in 9M FY25.Losses from discontinued operations narrowed significantly to ₹42.71 lakhs from ₹324.44 lakhs YoY.Board approved the re-appointment of the core promoter management team for a 3-year term starting April 2026.
👀 கவனிக்க வேண்டியவை
Investors should view the strong top-line and bottom-line growth as a positive sign of operational efficiency and scale. The continuity in leadership provides stability, though investors should monitor the final disposal of discontinued assets.
Bajaj Healthcare Seeks Shareholder Approval for 7 Director Appointments and Re-appointments
Bajaj Healthcare has issued a postal ballot notice to seek shareholder approval for the appointment of three Independent Directors and the re-appointment of four key executive leaders. The executive re-appointments, including the Chairman & Managing Director and Managing Director, are for three-year terms starting April 1, 2026. The three new Independent Directors are proposed for five-year terms to enhance board oversight and governance. Shareholders can cast their votes electronically from January 20 to February 19, 2026.
முக்கிய அம்சங்கள்
Re-appointment of Sajankumar Rameshwarlal Bajaj as CMD for a 3-year term starting April 1, 2026Proposed appointment of 3 new Independent Directors for 5-year terms to strengthen board governanceRe-appointment of Anil Champalal Jain as MD and two other Whole-Time Directors for 3-year termsE-voting period scheduled from January 20, 2026, to February 19, 2026Cut-off date for eligibility to vote is January 16, 2026
👀 கவனிக்க வேண்டியவை
Shareholders should review the profiles of the proposed directors and participate in the e-voting process to ensure leadership stability. Leadership continuity is generally a positive sign for the execution of the company's long-term strategy.
Bajaj Healthcare Q3 FY26: Revenue Up 31%, API Exports Surge 110% YoY
Bajaj Healthcare reported a strong Q3 FY26 with revenue growing 31.3% YoY to Rs. 1,612.2 Mn, primarily driven by a massive 109.8% surge in API exports. EBITDA margins improved slightly to 19.8%, leading to a 33.7% YoY increase in net profit to Rs. 156.7 Mn. The company achieved a significant regulatory milestone as the first Indian firm to receive CDSCO approval for Phase III trials of Suvorexant. For the nine-month period, PAT grew by 36.4%, reflecting sustained momentum in regulated markets and specialty drug development.
முக்கிய அம்சங்கள்
Revenue from operations grew 31.3% YoY to Rs. 1,612.2 Mn in Q3 FY26.API Export revenue more than doubled, growing 109.8% YoY to Rs. 486.8 Mn.EBITDA increased by 34.6% YoY to Rs. 323.3 Mn with margins expanding to 19.8%.Profit for the period (PAT) rose 33.7% YoY to Rs. 156.7 Mn.Filed 9 DMFs during the quarter, bringing the cumulative total to 69 filings.
👀 கவனிக்க வேண்டியவை
The company shows strong momentum in high-margin API exports and a successful transition towards regulated markets. Investors should monitor the progress of Phase III clinical trials for Suvorexant and Cenobamate as these represent high-value specialty opportunities.
Bajaj Healthcare Re-appoints Top Leadership Team for 3-Year Terms Starting April 2026
Bajaj Healthcare's Board has approved the re-appointment of its core leadership team, including Chairman & MD Sajankumar Bajaj and MD Anil Jain, for three-year terms. These appointments, effective from April 1, 2026, ensure management continuity for the company's API and formulation divisions. Additionally, two Whole-Time Directors, Ms. Namrata Bajaj and Mr. Pakshal Jain, were re-appointed for similar tenures. The board also approved the un-audited financial results for the quarter and nine months ended December 31, 2025, during the same session.
முக்கிய அம்சங்கள்
Re-appointment of Mr. Sajankumar Rameshwarlal Bajaj as Chairman & MD for 3 years effective April 1, 2026.Re-appointment of Mr. Anil Champalal Jain as Managing Director for a 3-year term ending March 31, 2029.Two Whole-Time Directors re-appointed for 3-year tenures to oversee Sales, Marketing, and API development.Board approved un-audited financial results for the quarter and nine months ended December 31, 2025.All leadership extensions are subject to shareholder approval via a forthcoming postal ballot.
👀 கவனிக்க வேண்டியவை
Investors should view these re-appointments as a positive sign of management stability and continuity. The primary focus should now shift to analyzing the Q3 FY26 financial results released in the same meeting.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
